Published in Gene Therapy Weekly, May 26th, 2005
"Recent evidence points to a novel function of human telomerase reverse transcriptase (hTERT) in promoting tumor cell survival, which might be independent of the telomere-elongating activity of the enzyme. To test this hypothesis, we evaluated comparatively the effects of telomerase inhibition, accomplished through antisense oligonucleotide-mediated interference with hTERT or human telomerase RNA component (hTERC), on the proliferative potential of DU145 human prostate cancer cells," investigators in Italy report.
"Exposure of cells to a 2'-O-methyl-RNA phosphorothioate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.